



**AMENDMENTS TO THE CLAIMS****Listing of Claims:**

Claims 1-2. (Canceled).


3. (Previously presented) The compound or compounds according to claim 34, selected from the group consisting of the compounds of formulae Ia, Ib, Ic and Id,




Ia



Ib



Ic



wherein



$R^7$ ,  $R^8$ ,  $p$ ,  $X$ ,  $Y$ ,  $R^9$ ,  $q$  and  $R^{10}$  are as defined in claim 34,

and tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios.



4. (Canceled).
5. (Previously presented) The compound or compounds according to claim 34, having formula A -NH-CO-B, wherein A- and -B are selected from the group consisting of,

	A-	-B
(1)		
(2)		
(3)		



(4)





(5)





(6)





(7)





(8)





(9)


















(10)





(11)










(26)





(27)





(28)





(29)




(30)





(31)





(32)





(33)





(34)





(35)





(36)





(37)





(38)





(39)





(40)





(41)




(42)





(43)





(44)




(45)




(46)















(61)





(62)





(63)




(64)





(65)





(66)





(67)





(68)





(69)





(70)





(71)





(72)





(73)





(74)





(75)





(76)



(77)



(78)




or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios.

Claims 6-8. (Canceled).

9. (Previously presented) A pharmaceutical composition, comprising one or more of the compound or compounds according to claim 34, or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios, in a pharmaceutical composition.
10. (Previously presented) The pharmaceutical composition according to claim 9, characterized in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.
11. (Previously presented) A process for the manufacture of a pharmaceutical composition, comprising one or more of the compound or compounds according to claim 34, or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios, and one or more compound or compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compound or compounds according to claim 34, is processed by mechanical means into a pharmaceutical composition that is suitable as dosage form for application and/or administration to a patient.
12. (Previously presented) A method comprising administering to a patient the compound or compounds according to claim 34, or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios, as a pharmaceutical composition.

Claims 13-28. (Canceled).

29. (Previously presented) A method for producing the compound or compounds of claim 34, or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios, comprising that
  - a) a compound of formula II




wherein

$L^1$  is H or a metal ion, and  $R^6$ ,  $R^7$ ,  $R^8$  and  $p$  are as defined in claim 34,

is reacted

b) with a compound of formula III,



wherein


$L^2$  is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and  $Y$ ,  $R^9$ ,  $q$ ,  $X$ ,  $Ar^2$ ,  $R^{10}$  and  $r$  are as defined in claim 34,

and optionally

c) isolating and/or treating the compound or compounds of claim 34 obtained by said reaction with an acid, to obtain the salt thereof.

Claims 30-33. (Canceled).

34. (Previously presented) A compound or compounds of formula I



wherein,

$Ar^2$  is pyridinyl,

$R^6$ ,  $R^7$  independently from one another, are H or unbranched or branched alkyl comprising 1 to 6 carbon atoms, optionally substituted by one or more Hal atoms,

$R^8$ ,  $R^9$  independently from one another, are selected from the group consisting of A, H, Hal and unbranched or branched alkyl comprising 1 to 6 carbon atoms, optionally substituted by one or more Hal atoms,

$R^{10}$  is selected from the group consisting of H, alkyl comprising 1 to 4 carbon atoms and  $(CH_2)_nCONR^{11}R^{12}$ ,

$R^{11}$ ,  $R^{12}$  independently from one another, are selected from the group consisting of H, Hal and branched or unbranched alkyl comprising 1 to 6 carbon atoms, optionally substituted by one or more Hal atoms,

$n$  is 0, 1, 2, 3, 4, or 5,

$X$  is O

$Y$  is O



p is 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,

r is 0, 1, 2 or 3,

and

Hal is selected from the group consisting of F, Cl, Br and I,

or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios.

35. (Currently amended) The compound or compounds according to claim 34, wherein

$R^6$ ,  $R^7$  independently from one another, are H or are selected from the group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, and tert.-butyl,

$R^8$ ,  $R^9$  independently from one another, are H or ~~hal~~ Hal or are selected from the group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, and tert.-butyl, and

~~hal~~ Hal is selected from the group consisting of F, Cl and Br,

or tautomeric forms, salts, stereoisomers or mixtures thereof in all ratios.